• Favourable safety profile of eftilagimod alpha in combination with pembrolizumab
• Deep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B respectively
• Disease Control Rate of 66% of patients in each Part A and B (24 patients in total)
Ann: Immutep presents positive TACTI-mel melanoma trial data, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.0¢ | 33.5¢ | $724.1K | 2.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 60483 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 55452 | 4 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |